CAL101 is an inhibitor of p110δ PI3K that is clinically used to treat leukemias such as mantle cell lymphoma and chronic lymphocytic leukemia (CLL). CAL101 exhibits anticancer chemotherapeutic and immunosuppressive activities. In mantle cell lymphoma cells, CAL101 induces G1 phase cell cycle arrest and apoptosis. In non-Hodgkin lymphoma and CLL cells, CAL101 inhibits downstream phosphorylation of Akt and induces apoptosis. Additionally, this compound inhibits cell chemotaxis, decreases chemokine production, inhibits migration, and prevents ERK- and Akt-dependent B-cell receptor signaling in CLL cells.